A phase 1 study of SEA-BCMA in patients with relapsed or refractory multiple myeloma Verified

What's the purpose of this trial?

This trial is testing a monoclonal antibody called SEA-BCMA. Researchers want to know what dose is safest, what side effects patients may have, and if SEA-BCMA will work to treat multiple myeloma.

SEA-BCMA is a type of treatment called a monoclonal antibody. Antibodies are part of your immune system. Usually, they help protect you from getting sick. With SEA-BCMA, we are using an antibody designed to stick to the multiple myeloma cells in your body. The antibody sends a signal to other cells in your immune system that kill the cancer cells. It also stops the multiple myeloma cells from getting a signal that makes them grow. The antibody may also stick to some non-cancer cells in your body.

They are asking you to be in this study because you have multiple myeloma that has come back or did not get better with your last therapy.

This trial is currently open and accepting patients.


What's being studied?

  • SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

What will happen during the trial?

This study has been planned in two parts, dose escalation and dose expansion.

  • Dose Escalation - This means a small group of patients will receive a dose of SEA-BCMA. If that dose is determined to be safe, a second group will receive a higher dose of SEA-BCMA. This will continue until researchers find the highest dose of SEA-BCMA that is tolerated without bad side effects.
  • Dose Expansion - Patients in this phase will receive the dose found to work best with the least side effects from phase 1. This dose is called the maximum tolerated dose (MTD).
  • Both Part 1 and 2 of this study will follow the same schedule.

This trial is open label, which means that both you and the researchers running the study will know what dose of SEA-BCMA you will receive.

SEA-BCMA will be given as an IV infusion on day 1 and day 15 of each 28 day treatment cycle. You can continue to receive SEA-BCMA as long as your myeloma doesn’t get worse, and you don’t develop bad side effects.

Other treatment schedules may be available as the study progresses.

After you have stopped receiving SEA-BCMA, study investigators will ask you to participate in a follow up visit or phone call every 3 months until the study ends.

You can decide to stop being in the study at any time. You can still go to your regular hospital or clinic for treatment after you leave this study.

If you decide to stop treatment with SEA-BCMA, you will still be asked to come back to the hospital or clinic for follow-up tests. You may also be asked to take part in follow-up phone calls and visits.

Financial Assistance

During the study, Seattle Genetics will pay for:

  • the study drug, SEA-BCMA
  • any procedures done only for the study

You or your insurance company will be billed for your regular medical care. It's possible your insurance may not cover all of your regular medical care costs. You are responsible for the part your insurance doesn’t pay. If you’re not sure how this applies to you, ask your doctor or the study staff.

You won’t be paid for taking part in this study or for any discoveries made in this study.

You may be able to have some of your costs for taking part in the study paid back, like travel and lodging. Please ask someone from the study staff for more information.


Additional Trial Information

Phase 1

Enrollment: 185 patients (estimated)

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

  • Are at least 18 years old
  • Have relapsed or refractory myeloma.
  • Have received at least 3 prior lines of therapy for your myeloma, including an immunomodulatory agent, proteasome inhibitor, and an anti-CD38 antibody and not have other therapies that could provide clinical benefit available
  • Have not previously had a targeted BCMA therapy.
  • Have not had an allogeneic stem cell transplant.
  • No prior CAR T-cell therapy unless completed at least 8 weeks prior to first dose of SEA-BCMA
View Additional Criteria

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

Stanford Cancer Institute

Stanford, CA

Accepting

Colorado

Rocky Mountain Cancer Center Aurora

Aurora, CO

Accepting

Florida

Iowa

Kansas

University of Kansas Cancer Center

Kansas City, KS

Accepting

Missouri

New York

Weill Cornell Medicine

New York, NY

Accepting

University of Rochester Medical Center James P. Wilmot Cancer Center

Rochester, NY

Accepting

Oregon

Willamette Valley Cancer Institute (Eugene)

Eugene, OR

Accepting

Texas

Texas Oncology Austin Midtown

Austin, TX

Accepting

Washington

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Seattle Genetics to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors